



JFL LIFE SCIENCES LIMITED

Date: May 29, 2026

To,
The Manager,
Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

NSE Symbol: JFLIFE; ISIN: INE0LA901015

Dear Sir,

Sub: - OUTCOME OF THE BOARD MEETING

The Board of Directors of **JFL Life Sciences Limited**, in their meeting held on **Friday, May 29, 2026** which commenced at **04:00 PM** and concluded at **05:00 pm** at the registered office of the company situated at 309, Satyam Mall, Opp. Saman Complex, Nr. Vishweshwar Mahadev Mandir, Satellite, Ahmedabad,, Gujarat, 380015.

- Pursuant to the Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we hereby inform that the Board Considered and approved the audited financial results of the Company for the **Quarter Ended and financial year ended March 31, 2026**, along with the Audit Report of the Statutory Auditors in respect of the audited financial results of the Company.
- Appointment of **Mr. Jignesh Sharma, (Mem No.: 191020), Partner, J N GUPTA & Co. LLP, Chartered Accountants FRN: 006569C/W100892**, as an Internal Auditor for the next financial year for **2026-2027**.
- Any other item, if discussed and approved, will be disclosed separately as per applicable SEBI regulations.

We request you to kindly take note of the same and oblige.

Thanking You
Yours Truly,
For JFL LIFE SCIENCES LIMITED

SMIRAL ASHWINKUMAR PATEL
Managing director
Din: 00769486



JFL LIFE SCIENCES LIMITED

Date: May 29, 2026

To,
The Manager,
Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Dear Sir/Madam,

**SUB: DECLARATION ON UNMODIFIED OPINIONS UNDER REGULATION 33(3)(d) OF
SEBI (LODR) REGULATIONS, 2015**

NSE Symbol: JFLIFE; ISIN: INE0LA901015

Pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we declare that M/s. Doshi & Doshi & Co. Statutory Auditors of the Company have submitted the Audit reports with unmodified opinion(s) for Annual Audited Financial Results (Standalone and Consolidated) of the Company for the financial year ended on March 31, 2026.

Please take the same on record.

Thanking You,

Yours Faithfully.

For JFL LIFE SCIENCES LIMITED

SMIRAL ASHWINKUMAR PATEL
Managing director
Din: 00769486

Independent Auditor's Report on Quarterly Financial Results and Year to date Audited Financial Results of M/s. JFL LIFE SCIENCES LIMITED Pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors
M/s. JFL LIFE SCIENCES LIMITED
309, SATYAM MALL, OPP. SAMAN COMPLEX,
NR. VISHWESHWAR MAHADEV MANDIR, SATELLITE,
AHMEDABAD, GUJARAT - 380015.

Report on the Audit of the Financial Results

Opinion

We have audited the accompanying statement of the Quarterly and year to date financial results of JFL LIFE SCIENCES LIMITED (the "Company") for the Quarter ended 31st March, 2026 and the year-to-date results for the period from 01st April, 2025 to 31st March, 2026 (the "Statement"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the Quarter ended 31st March, 2026 as well as the year-to-date results for the period from 01st April, 2025 to 31st March, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Financial Results

This Statement, which includes the financial results is the responsibility of the Company's Board of Directors, and has been approved by them for the issuance. The Statement has been compiled from the related audited financial statements for the year ended March 31, 2026. This responsibility includes preparation and presentation of the Financial Results for the Quarter and year ended March 31, 2026 that give a true and fair view of the net profit and other Comprehensive Income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally

☎ 9167 404 303
✉ chintan@ddco.in
🌐 www.ddco.in

📍 **Ahmedabad Branch**
C 908, Stratum @ Venus Ground,
NR Jhansi Ki Rani Statue,
Nehrunagar, Ahmedabad - 380015

📍 **Mumbai Branch**
119, Plot No. 7, Near F M Banquets,
Udyog Nagar, Goregaon West,
Mumbai - 400104.



accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to

☎ 9167 404 303

✉ chintan@ddco.in

🌐 www.ddco.in

📍 **Ahmedabad Branch**

C 908, Stratum @ Venus Ground,
NR Jhansi Ki Rani Statue,
Nehrunagar, Ahmedabad - 380015

📍 **Mumbai Branch**

119, Plot No. 7, Near F M Banquets,
Udyog Nagar, Goregaon West,
Mumbai - 400104.



the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Company to express an opinion on the financial results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the financial results of which we are the independent auditors.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The figures for Quarter ended March 31, 2026 and Quarter ended March 31, 2025 are the balancing figures between respective audited figures in respect to the full Financial Year up to March 31, 2026 and Financial Year upto March 31 2025, and the unaudited published year to date figures up to December 31, 2025 and December 31, 2024 respectively being the date of the end of the third quarter of financial year which were subjected to limited review by us, as required under the Listing regulations. Our opinion is not modified in respect of this matter.

Yours Faithfully

For **Doshi Doshi & Co**,
Chartered Accountants
Firm Registration No.: 153683W



Chintan Doshi

Partner

Membership No.: 158931

UDIN: 26158931TQQKDU4965



Place: Ahmedabad

Date: May 29, 2026



JFL LIFE SCIENCES LIMITED

STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2026

(Rs. In Lakhs)

Sr. No.	PARTICULARS.	Quarter Ended on			Year Ended on	
		31.03.2026 (Refer Note 4)	31.12.2025 (Unaudited)	31.03.2025 (Refer Note 4)	31.03.2026 (Audited)	31.03.2025 (Audited)
	INCOMES					
I	Revenue from Operations	6,305.44	2,683.62	1,173.21	13,138.26	8,204.23
II	Other Income	4.03	1.40	0.13	6.90	1.01
III	Total Income (I + II)	6,309.47	2,685.02	1,173.34	13,145.16	8,205.24
IV	EXPENSES					
(a)	Cost of materials consumed	5,781.90	2,299.41	752.03	11,505.53	6,677.44
(b)	Changes of Inventories of Finished Goods, Work in Progress, Stock in Trade	(0.46)	(1.84)	6.07	(7.52)	(66.30)
(c)	Employee benefits expense	35.11	26.80	26.75	111.56	101.09
(d)	Finance Cost	103.43	38.42	33.17	210.59	108.12
(e)	Depreciation and Amortisation Expense	27.43	26.86	35.51	107.52	99.25
(f)	Other Expenses	137.33	24.58	250.81	357.57	672.10
	TOTAL EXPENSES (IV) (a to f)	6,084.74	2,414.22	1,104.34	12,285.26	7,591.70
V	Profit/(Loss) before Exceptional Items and Tax (III-IV)	224.73	270.80	69.00	859.90	613.54
VI	Exceptional Items & Extraordinary Item					
VII	Profit/ (Loss) Before Tax (V-VI)	224.73	270.80	69.00	859.90	613.54
VIII	TAX EXPENSES					
(a)	Current Tax	53.17	69.39	19.46	215.82	152.87
(b)	Deffered Tax	5.69	(0.59)	41.25	3.98	44.90
	Total Tax Expenses	58.86	68.80	60.71	219.80	197.78
IX	NET PROFIT / (LOSS) AFTER TAX	165.87	201.99	8.29	640.10	415.77
X	Items that will not be reclassified to profit or loss					
(i)	Re-measurement gains / (loss) on defined benefit plans	0.53	0.50	(0.36)	1.70	(0.36)
(ii)	Income tax relating to items that will not be reclassified to profit or loss	(0.13)	(0.13)	0.09	(0.43)	0.09
	Other comprehensive income, net of tax	0.39	0.37	(0.27)	1.27	(0.27)
	Total comprehensive income for the quarter / year	166.27	202.36	8.02	641.38	415.50
XI	Paid up Equity Share Capital (Rs. 10 Face value per share)	3,299.53	3,299.53	3,299.53	3,299.53	3,299.53
XII	Other Equity				1,287.39	646.01
XIII	Earning Per Share (In Rupees)					
(i)	Basic	0.50	0.61	0.03	1.94	1.26
(ii)	Diluted	0.50	0.61	0.03	1.94	1.26

NOTES:
1 These financial result were reviewed by the Board of Directors and Audit Committee thereafter have been approved by the board of directors at its meeting held on May 29, 2026. The Statutory Auditors have carried out audit of the financial result for the year ended on March 31, 2026.

2 Financial results for all the periods presented have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended from time to time) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

3 Company has only one reportable segment - Pharmaceuticals Manufacturing.

4 The figures for Quarter ended March 31, 2026 and Quarter ended March 31, 2025 are the balancing figures between respective audited figures in respect to the full Financial Year up to March 31, 2026 and Financial Year upto March 31 2025 and the unaudited published year to date figures up to December 31, 2025 and December 31, 2024 respectively being the date of the end of the third quarter of financial year which were subjected to limited review.

5 Figures for the previous period have been regrouped/ rearranged/ reclassified wherever considered necessary to correspond with the current period's classification/group's disclosure.

For JFL Life Sciences Limited

Smiral A. Patel
Managing Director
DIN : 00769486
Date : May 29, 2026
Place : Ahmedabad

Registered Office Address : 309, Satyam Mall, Opp. Saman Complex, Nr.Vishweshwar Mahadev Mandir, Satellite, Ahmedabad-380015.
Unit-I : 615, G.I.D.C. Estate Kerala, Bavla, Ahmedabad, Gujarat-382220.
Unit-II : 406,407, G.I.D.C. Kerala, Bavla, Ahmedabad, Gujarat-382220.

CIN : L24230GJ2010PLC060417 | Contact No.: 9377295575 | Email : info@jfllifesciences.com | Website : www.jfllifesciences.com




JFL LIFE SCIENCES LIMITED

STATEMENT OF ASSETS AND LIABILITIES AS AT 31st MARCH, 2026

(Rs. In Lakhs)

PARTICULARS	AS AT 31 Mar 2026	AS AT 31 Mar 2025
	AUDITED	AUDITED
Assets		
Non-current assets		
Property, plant and equipment	1,195.21	961.46
Right of Use Assets	258.75	262.18
Non - Current Financial Assets		
(i) Other financial assets	20.62	17.36
Total Non-Current Assets	1,474.58	1,241.00
Current assets	3,454.80	2,324.11
Inventories		
Current Financial assets	5,326.06	3,494.51
(i) Trade receivables	86.30	3.39
(ii) Cash and cash equivalents	59.91	3.00
(iii) Bank balances other than cash and cash equivalents	2.46	0.16
(iv) Other financial assets	220.50	125.23
Other current assets	9,150.03	5,950.40
Total Current Assets	10,624.61	7,191.40
Total Assets		
Equity and liabilities		
Equity	3,299.53	3,299.53
Equity share capital	1,287.39	646.01
Other equity	4,586.92	3,945.54
Total equity		
Liabilities		
Non-current liabilities		
Non - Current Financial liabilities	688.19	37.98
i. Borrowings	13.94	13.00
Provisions	36.72	32.73
Deferred tax liabilities (Net)	738.85	83.71
Total Non-Current Liabilities		
Current liabilities		
Current Financial liabilities	1,484.69	1,021.04
i. Borrowings		
ii. Trade payables		
- Total outstanding dues of micro and small enterprises	2,928.31	1,775.71
- Total outstanding dues of creditors other than micro and small enterprises	390.74	138.68
iii. Other financial liabilities	65.26	8.48
Provisions	429.85	218.23
Current tax liabilities (Net)	5,298.84	3,162.15
Total current liabilities	6,037.69	3,245.86
Total liabilities		
Total equity and liabilities	10,624.61	7,191.40

For JFL Life Sciences Limited


Smiral A. Patel
Managing Director
DIN : 00769486
Date : May 29, 2026
Place : Ahmedabad

Registered Office Address : 309, Satyam Mall, Opp. Saman Complex, Nr. Vishweshwar Mahadev Mandir, Satellite, Ahmedabad-380015.
Unit-I : 615, G.I.D.C. Estate Kerala, Bavla, Ahmedabad, Gujarat-382220.
Unit-II : 406,407, G.I.D.C. Kerala, Bavla, Ahmedabad, Gujarat-382220.
CIN : L24230GJ2010PLC060417 | Contact No.: 9377295575 | Email : info@jfllifesciences.com | Website : www.jfllifesciences.com




JFL LIFE SCIENCES LIMITED

STATEMENT OF CASH FLOW FOR THE YEAR ENDED 31st MARCH, 2026

(Rs.In Lakhs)

Particulars	For the Year ended 31 March 2026	For the Year ended 31 March 2025
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	861.18	613.28
Finance cost	210.59	108.12
Depreciation and amortisation income	107.52	99.25
Interest income	(2.56)	(0.78)
Operating profit before working capital changes	1,176.72	819.86
Movements in working capital:		
Adjusted for (Increase)/Decrease in operating assets:		
Long-Term Loans and advances	(3.26)	(2.09)
Inventories	(1,130.69)	(740.78)
Trade Receivables	(1,831.54)	(908.35)
Other Current Assets	(95.27)	19.24
Adjusted for Increase/(Decrease) in operating liabilities:		
Trade Payables	1,152.60	523.68
Provisions	57.71	4.91
Other Current Financial Liabilities	244.86	30.28
Cash generated (used in)/from operations	(428.87)	(253.23)
Income tax paid	(4.20)	(102.48)
Net cash flow generated (used in)/from operating activities (A)	(433.08)	(355.72)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property plant & equipment	(337.85)	(39.52)
Interest received	0.27	3.35
Proceeds / (Investment) from fixed deposits	(56.91)	37.70
Net cash flow from/(used in) investing activities (B)	(394.48)	1.52
C. CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of long and short-term borrowings	1,113.85	489.79
Dividend paid during the year	-	(27.50)
Finance cost	(203.39)	(108.12)
Net cash flow from / (used in) financing activities (C)	910.46	354.17
Net increase / (decrease) in cash and cash equivalents (A+B+C)	82.91	(0.02)
Cash and cash equivalents at the beginning of the year	3.39	3.41
Cash and cash equivalents at the end of the year	86.30	3.39

For JFL Life Sciences Limited


Smiral A. Patel
Managing Director
DIN : 00769486
Date : May 29, 2026
Place : Ahmedabad

Registered Office Address : 309, Satyam Mall, Opp. Saman Complex, Nr. Vishweshwar Mahadev Mandir, Satellite, Ahmedabad-380015.

Unit-I : 615, G.I.D.C. Estate Kerala, Bavla, Ahmedabad, Gujarat-382220.

Unit-II : 406,407, G.I.D.C. Kerala, Bavla, Ahmedabad, Gujarat-382220.

CIN : L24230GJ2010PLC060417 | Contact No.: 9377295575 | Email : info@jfllifesciences.com | Website : www.jfllifesciences.com



JFL LIFE SCIENCES LIMITED

Date: May 29, 2026

To,
The Manager,
Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Dear Sir/Madam,

Subject: Compliance of Regulation 23(9) SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015

NSE Symbol: JFLIFE; ISIN: INE0LA901015

With regard to captioned subject, kindly find enclosed herewith disclosures of related party transactions on a consolidated basis for the year ended on 31st March, 2026 in compliance of Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015.

You are requested to take the same on your record.

Thanking You,

Yours faithfully,
For JFL LIFE SCIENCES LIMITED

SMIRAL ASHWINKUMAR PATEL
Managing director
Din: 00769486

Disclosure of related party transactions every six months for the period of March, 2026

										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
S.No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction (see Note 5)	Value of the related party transaction as approved by the audit committee (see Note 6a)	Value of transaction during the reporting period (see Note 6b)	In case monies are due to either party as a result of the transaction (see Note 1)		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments			
									Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc)	Cost (see Note 7)	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary													
1	JFL Life Sciences Limited	AACCJ5298E	SMIRAL ASHWINKUMAR PATEL	ABBH55117A	Managing Director of the listed entity	Remuneration	18.00	18.00	0.00	0.00							
2	JFL Life Sciences Limited	AACCJ5298E	TEJAL SMIRAL PATEL	APGPP6312M	Whole Time Director and CFO of the listed entity	Remuneration	15.00	15.00	0.00	0.00							
3	JFL Life Sciences Limited	AACCJ5298E	SMIRAL ASHWINKUMAR PATEL	ABBH55117A	Managing Director of the listed entity	Loan Taken	211.51	211.51	0.00	0.00							
4	JFL Life Sciences Limited	AACCJ5298E	TEJAL SMIRAL PATEL	APGPP6312M	Whole Time Director and CFO of the listed entity	Loan Taken	5.00	5.00	0.00	0.00							
5	JFL Life Sciences Limited	AACCJ5298E	SMIRAL ASHWINKUMAR PATEL	ABBH55117A	Managing Director of the listed entity	Loan Repaid	-211.51	0.00	0.00	0.00							
6	JFL Life Sciences Limited	AACCJ5298E	TEJAL SMIRAL PATEL	APGPP6312M	Whole Time Director and CFO of the listed entity	Loan Repaid	-5.00	0.00	0.00	0.00							
7	JFL Life Sciences Limited	AACCJ5298E	Hiral Mahavirsinh Chudasama	BZIPK1864L	Company Secretary of the listed entity	Remuneration	2.55	2.55	0.00	0.00							
8	JFL Life Sciences Limited	AACCJ5298E	Hiral Mahavirsinh Chudasama	BZIPK1864L	Company Secretary of the listed entity	Amount Payable	0.21	0.21	0.00	0.21							

Notes:

The details in this disclosure are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.

- Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
- Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.
- For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six months period shall apply accordingly.
- Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type. However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
- In case of a multi-year related party transaction:
 - The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".
 - The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".
 - "Cost" refers to the cost of borrowed funds for the listed entity.
- Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable / offered to all shareholders/ public shall also be reported.

**BY ORDER OF THE BOARD OF DIRECTORS ,
FOR, JFL Life Sciences Limited**

**SMIRAL ASHWINKUMAR PATEL
(Managing Director)
(DIN:00769486)**

**DATE: 29.05.2026
PLACE: AHMEDABAD**